Experts opinions and views

Read below experts opinions on immunological safety for innovative healthcare products

Disclaimer: The views and opinions expressed in these articles are solely those of the author(s) and do not necessarily represent the views and opinions of Nanobiose and/or any/all of its staff.

  • Caster JM, Patel AN, Zhang T, Wang A (2017) Investigational nanomedicines in 2016: a review of nanotherapeutics currently undergoing clinical trials. WIRES Nanomed Nanobiotechnol. 9(1) e1416. Since the introduction of liposomal doxorubicin in clinical practice (1995), approx. 50 nanoparticle-based drugs have been approved for therapeutic...

  • THE CYTOKINE RELEASE ASSAY (CRA)   Even before interleukin-1 was cloned (1984), some adverse effects of early immunomodulatory drugs, such as levamisole or tilorone, were hypothesized to be due to ‘direct macrophage activation’. Subsequently, a variety of vaccines, therapeutic proteins or monoclonal antibodies were shown...

  • The term ‘drug-induced hypersensitivity’ is increasingly preferred to ‘drug allergy’ as it is often ambiguous, if not misleading. Drug-induced hypersensitivity reactions are either immune- or non-immune mediated. Immune-mediated – formerly called immuno-allergic – reactions are always unexpected and so far, unpredictable based on nonclinical findings,...

  • With the aim of getting more and better insights into living systems, the real time follow-up of protein secretion remains an important objective. Several issues have to be simultaneously addressed to real this holly Graal. First, the transducing method should enable the real-time analysis. Often,...